This up-and-coming cancer treatment could be a $25 billion market opportunity — it's already a hotbed for M&A
Publishing timestamp: 2024-05-23 12:46:58
Summary
Big pharma is investing billions in targeted radiopharmaceutical therapy, with Novartis, Eli Lilly, Bristol-Myers Squibb, and AstraZeneca making significant acquisitions in the space. The market is seen as a $25 billion opportunity, with companies developing new treatments for various types of cancer using radiopharmaceuticals. There is a focus on improving existing treatments and expanding into attacking different cancer tumors, with potential for significant growth in the future.
Sentiment: POSITIVE
Tickers: BMY, LLY, NOV.N-CH, AZN-GB, FUSN, NVS,
Keywords: eli lilly and co, investment strategy, novartis ag, fusion pharmaceuticals inc, biotech and pharmaceuticals, breaking news: investing, health care industry, pharmaceuticals, bristol-myers squibb co, astrazeneca plc, business news,